PPARGC1A and myeloid sarcoma: Despite the indifferent findings in the human CSF and the lack of a potential role as a biomarker, the involvement and potential therapeutic aspects of PGC-1α needs to be directly assessed in EAE/MS, due to its proposed immunomodulatory and neuroprotective features.